On “Pathogenesis and Management of Postoperative Ileus” (Clin Colon Rectal Surg 2009;22:47–50)

REFERENCES

• 1 Carroll J, Alavi K. Pathogenesis and management of postoperative ileus.  Clin Colon Rectal Surg. 2009;  22(1) 47-50
• 2 Wolff B G, Michelassi F, Gerkin T M Alvimopan Postoperative Ileus Study Group et al. Alvimopan, a novel, peripherally acting mu opioid antagonist: results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial of major abdominal surgery and postoperative ileus.  Ann Surg. 2004;  240(4) 728-734 discussion 734-735
• 3 Delaney C P, Weese J L, Hyman N H Alvimopan Postoperative Ileus Study Group et al. Phase III trial of alvimopan, a novel, peripherally acting, mu opioid antagonist, for postoperative ileus after major abdominal surgery.  Dis Colon Rectum. 2005;  48(6) 1114-1125 discussion 1125-1126 author reply 1127-1129
• 4 Herzog T J, Coleman R L, Guerrieri Jr J P et al.. A double-blind, randomized, placebo-controlled phase III study of the safety of alvimopan in patients who undergo simple total abdominal hysterectomy.  Am J Obstet Gynecol. 2006;  195(2) 445-453
• 5 Viscusi E R, Goldstein S, Witkowski T et al.. Alvimopan, a peripherally acting mu-opioid receptor antagonist, compared with placebo in postoperative ileus after major abdominal surgery: results of a randomized, double-blind, controlled study.  , [published erratum appears in Surg Endosc 2006;20:537] Surg Endosc. 2006;  20(1) 64-70
• 6 Ludwig K, Enker W E, Delaney C P et al.. Gastrointestinal tract recovery in patients undergoing bowel resection: results of a randomized trial of alvimopan and placebo with a standardized accelerated postoperative care pathway.  Arch Surg. 2008;  143(11) 1098-1105
• 7 Adolor Corporation .Entereg^® (alvimopan) capsules. Prescribing information. Available at: http://www.entereg.com/pdf/prescribing-information.pdf Accessed January 5, 2010